CIRRO E-Commerce enters Polish market and joins E-Commerce Connect Poland as a platinum sponsor
WARSAW, Poland, April 30, 2025 (GLOBE NEWSWIRE) -- CIRRO E-Commerce, a leading global e-commerce logistics solution provider, announces its official entry into the Polish market. To mark this strategic expansion, the company will participate as a Platinum Sponsor at the upcoming E-Commerce Connect Poland event on May 20-21, reflecting its dedication to supporting the growth of Poland's thriving e-commerce ecosystem.
According to The Observatory of Economic Complexity (OEC), Poland continues to serve as a significant hub for European and global exports, with top markets including Germany, the UK, Czechia, France, and Italy. Given its strong trade infrastructure, Poland is increasingly becoming vital in European e-commerce, presenting a prime opportunity for CIRRO E-Commerce's logistics solutions.
CIRRO E-Commerce introduces a comprehensive logistics solution for modern e-commerce. Polish merchants now gain access to end-to-end services, including the company's delivery network in France, the Netherlands, and Italy, and reliable European shipping with 2–4 day delivery from Poland to key destinations like Germany, France, Spain, the UK, and more. Through a single API, CIRRO enables global growth with IOSS/DDP shipping, returns management, customs clearance, and full traceability.
'We are thrilled to bring CIRRO E-Commerce's expertise to the Polish market at such a pivotal time,' said Pawel Wasilewski, Sales Manager at CIRRO E-Commerce. 'Polish merchants are scaling faster than ever and need a logistics partner to keep pace with their ambitions. Our solutions are built to help them reach more customers more efficiently across Europe and beyond.'
CIRRO E-Commerce's Platinum Sponsorship of E-commerce Connect Poland highlights a shared mission to drive sustainable e-commerce growth. The event connects top e-commerce leaders and solution providers through curated one-on-one meetings, case studies, and premium networking experiences to foster strong and lasting partnerships.
CIRRO E-Commerce is proud to support Poland's e-commerce community and help local brands expand their reach across Europe and beyond.
About CIRRO E-CommerceCIRRO E-Commerce is an e-commerce logistics provider committed to providing seamless, end-to-end, cross-border logistics services. Thanks to the significant strengths, the company is changing the game regarding flexibility, reliability, cost efficiency, advanced technology, and customer-centricity. These include a robust transportation network, local teams of industry experts, and an extensive physical footprint in over 40 countries, including the U.S., the UK, the EU, and Australia.
For further information, please contact:Email:branding@cirroecommerce.com Website:www.cirroecommerce.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8e34de45-4078-4994-bda1-60c0ecbca250Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
19 minutes ago
- Fox News
The Story w/ Martha MacCallum - Monday, June 2
All times eastern FOX News Radio Live Channel Coverage WATCH LIVE: Second lady Usha Vance and Commerce Secretary Howard Lutnick speak at the U.S.-India Strategic Partnership Forum Annual Leadership Summit
Yahoo
19 minutes ago
- Yahoo
Saus Trades' Latest eBook Helps Traders Tackle the Psychological Barriers to Consistent Profitability
The Trader's Mind bridges the gap between strategy and success, offering tools like trading journals, breathing techniques, and mindset frameworks. Designed for daily use, it's been embraced by over 20,000 traders, earning a 4.5-star Courtesy of Saus Trades EDMONTON, Alberta, June 02, 2025 (GLOBE NEWSWIRE) -- Saus Trades, the digital brand redefining trading psychology, has launched The Trader's Mind, a breakthrough eBook built to help traders conquer the #1 reason 90 percent of them fail: the mental game. While most trading resources obsess over charts and technical analysis, this guide tackles the emotional chaos that wrecks consistency and destroys confidence. The Trader's Mind shifts the focus from tactics to transformation. It offers real-world tools to sharpen emotional discipline and master decision-making under pressure. Inside, traders will find breathing methods, mental reset frameworks, guided journal pages, and practical strategies to stay calm, clear, and locked in, even in high-stakes market moments. During its pre-launch period, The Trader's Mind exploded in popularity, reaching over 20,000 traders across the globe with a 4.5-star rating based on thousands of testimonials. Readers say they're making faster, more focused decisions, overcoming emotional impulses, and finally executing trades with clarity. 'Our goal was not just to create a book, it is to revolutionise the culture of trading,' said Kaitana Purchase and Emma Bell, co-CEOs of Saus Trades. 'We are here to bridge the gap between knowing how to trade and having the mindset to actually do it, consistently and confidently.' This eBook is more than a helpful guide, rather a psychological performance tool. Whether traders are bouncing back from a loss, stuck in hesitation, or chasing the next high, The Trader's Mind gives traders the internal structure to stay grounded and make elite-level decisions in real time. Saus Trades has coined this core concept as 'emotional discipline,' the ability to stick to traders' strategy regardless of fear, greed, or uncertainty. It's this skill that separates winning traders from everyone else, and it's what The Trader's Mind was built to develop. 'Emotional mastery isn't optional, it's the difference between burnout and breakthrough,' says Bell. 'We made this eBook for traders who are ready to stop sabotaging themselves and start showing up like professionals.' With guided exercises, self-assessment tools, and plug-and-play routines, the eBook helps traders uncover their mental blocks, build new habits, and create an environment where discipline becomes second nature. Already serving traders in the U.S., Canada, U.K., Australia, and the UAE, Saus Trades is scaling fast. Its no-fluff, psychology-first approach stands out in an industry dominated by technical analysis, and it is catching fire with traders who want real results. The launch of The Trader's Mind is timed as the trading community becomes more aware that psychology, not strategy, is the real battleground, and Saus Trades is stepping in with the exact tools traders have been missing. To celebrate, Saus Trades is offering new customers 10 percent off with code WELCOME10. This discount is part of the brand's mission: to make elite mental training accessible to every trader, no matter their level or capital. Learn more about The Trader's Mind and claim a copy at About Saus Trades Founded by CEOs Kaitana Purchase and Emma Bell, Saus Trades is on a mission to change how traders win. With psychology-forward resources and cutting-edge mental frameworks, the brand is empowering traders to master their minds and build lasting, consistent success in the markets. Contact Information Kaitana PurchaseCEO & FounderSaus Tradesadmin@ Canada A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its Phase II study of the MDM2-p53 inhibitor alrizomadlin (APG-115) as a single agent or in combination with PD-1 inhibitor toripalimab in patients with advanced adenoid cystic carcinoma (ACC) or other solid tumors in a poster presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting. Alrizomadlin is the first MDM2-p53 inhibitor to enter clinical development in China and a key investigational drug candidate in Ascentage Pharma's apoptosis-targeted pipeline with global first-in-class potential. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. Returning to the ASCO Annual Meeting for the eighth consecutive year, Ascentage Pharma has garnered growing interest from the global research community. This year, two studies of the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin, key drug candidates in the company's apoptosis-targeted pipeline, have been selected for presentations, including an oral presentation, at the ASCO Annual Meeting. These clinical data on alrizomadlin in ACC and other solid tumors demonstrated the antitumor activity of alrizomadlin monotherapy in patients with advanced ACC or malignant peripheral nerve sheath tumor (MPNST). Moreover, alrizomadlin in combination with toripalimab was well tolerated and showed therapeutic potential in MPNST, biliary-tract cancer (BTC), and liposarcoma (LPS). Prof. Ye Guo, MD, a Principal Investigator of the study from the Department of Medical Oncology, Shanghai East Hospital, noted, 'ACC is a rare cancer type that lacks effective treatment options, and the treatment with antiangiogenic tyrosine kinase inhibitors faces certain limitations and safety concerns. At ASCO 2025, our team presented data of alrizomadlin in patients with ACC that demonstrated an objective response rate (ORR) of 16.7% and a disease control rate (DCR) of 100%. These results suggest that the targeted inhibition of the MDM2-p53 pathway has antitumor activity in ACC; therefore, it can potentially offer a new treatment strategy to patients with ACC.' Prof. Ning Li, MD, a Principal Investigator of the study from the Chinese Academy of Medical Sciences Cancer Hospital, commented, 'Currently, there are limited treatment options for patients with sarcomas such as MPNST and LPS. In this study, alrizomadlin both as a monotherapy and in combination with a PD-1 therapy, showed favorable antitumor activity in MPNST. The clinical benefit was particularly notable in patients who received the combination regimen, with two patients with MPNST achieving long-term responses that lasted more than 60 and 96 weeks, respectively. Furthermore, alrizomadlin in combination with a PD-1 therapy also showed clinical activity in LPS. These results suggest that alrizomadlin monotherapy and combination regimens may bring clinical benefit to more patients with sarcoma.' Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Alrizomadlin is an investigational drug with global first-in-class potential. The clinical data presented at this year's ASCO Annual Meeting demonstrated the therapeutic potential of alrizomadlin, both as a monotherapy and in combinations, in ACC and other solid tumors, and underscored the synergistic effects between alrizomadlin and immunotherapies, thus suggesting a promising therapeutic strategy for various solid tumors. We are focused on addressing unmet clinical needs in China and around the world, and intend to further accelerate our clinical programs to advance more novel treatment options for patients as soon as possible.' Highlights of this abstract selected for presentation at ASCO 2025 are as follows: A Phase 2 Study of Novel MDM2 Inhibitor Alrizomadlin (APG-115) With or Without Toripalimab in Patients with Advanced Adenoid Cystic Carcinoma (ACC) or Other Solid Tumors Abstract #: 6102 Format: Poster Presentation Session Title: Head and Neck Cancer Principal Authors: Ye Guo, MD, Department of Medical Oncology, Shanghai East Hospital, China; Ning Li, MD, Chinese Academy of Medical Sciences Cancer Hospital, China; Xing Zhang, MD, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, China; Meiyu Fang, MD, Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, China; Shuhang Wang, MD, Chinese Academy of Medical Sciences Cancer Hospital, China, et al. Highlights: Alrizomadlin is a novel investigational oral MDM2 inhibitor that has shown a manageable safety profile with initial clinical activity in ACC. As of the data cutoff date of February 13, 2025, 57 patients with advanced ACC, malignant peripheral nerve sheath tumor (MPNST), liposarcoma (LPS), biliary-tract cancer (BTC), and other tumors were enrolled. Alrizomadlin monotherapy showed encouraging antitumor activity in patients with advanced ACC or MPNST. Alrizomadlin in combination with toripalimab was also well tolerated and demonstrated antitumor activity in patients with MPNST, BTC, and LPS. In the monotherapy arm, 17 patients were efficacy-evaluable. The ORR was 16.7%, and the DCR was 100% in 12 patients with ACC. The DCR was 80% in 5 patients with MPNST, 4 of whom achieved stable disease (SD). In 24 safety-evaluable patients, 33.3% reported grade 3 or higher treatment-related adverse events (TRAEs). Three patients (12.5%) experienced treatment-related serious adverse events (SAEs). One patient discontinued treatment because of TRAE. In the combination arm, 29 patients were efficacy-evaluable. The ORR was 16.7% and the DCR was 100% in 6 patients with BTC. The ORR was also 16.7% and the DCR was 66.7% in 6 patients with LPS. Two patients with MPNST had confirmed partial response (PR) with prolonged progression free survival (PFS) of 60+ weeks and 96+ weeks, respectively. In 27 safety-evaluable patients treated with alrizomadlin at the 150 mg dose level, 12 (44.4%) experienced grade 3 or higher TRAEs. Treatment-related SAEs were reported in 8 patients (29.6%). One patient discontinued treatment because of TRAE. *Alrizomadlin (APG-115) is an investigational compound and has not been approved by the US FDA. About Ascentage PharmaAscentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph+ ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematological malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with sub-optimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ContactsInvestor Relations:Hogan Wan, Head of IR and StrategyAscentage 512 85557777 Stephanie CarringtonICR (646) 277-1282 Media Relations:Sean LeousICR (646) 866-4012Sign in to access your portfolio
